Literature DB >> 3484633

Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro.

F Dammacco, G Iodice, N Campobasso.   

Abstract

Eight adult patients with idiopathic thrombocytopenic purpura (ITP) were given two 5-d courses of intermediate (250 mg/kg body weight/d) to high dose (400 mg/kg body weight/d) intravenous infusions of human plasmin-cleaved Ig, at 15-30 d intervals. Three patients also were given single booster infusions (400 mg/kg body weight for 1 d) of a different preparation, S-sulfonated Ig. As expected, significant though transient rises in the platelet count were consistently observed in all patients. The mean platelet count increase was 95 600/mm3 after the first course, and 143 500/mm3 after the second course. Similar effects of lower magnitude were obtained several times in the patients given single booster doses. In three patients, platelet-bound IgG levels were decreased in association with Ig therapy. Phenotypic analysis of T cell subsets before starting Ig therapy and at the end of the second high dose course of intravenous Ig treatment revealed significant reductions in the proportion of T4+ lymphocytes in five patients and relative increases in the percentage of T8+ cells after therapy. As the overall proportion of T3+ cells remained unchanged, the T4+/T8+ ratio was therefore decreased. The total number of circulating lymphocytes was also decreased following therapy. In addition, PWM-driven Ig biosynthesis in vitro was significantly impaired after therapy in most patients, the capacity to synthesize IgG being mainly affected. It is concluded that, in addition to the reported transient blockade of the reticuloendothelial system, non-specific suppression of polyclonal Ig biosynthesis induced by the high dose Ig infusions also contributes to the net increase in platelet count.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484633     DOI: 10.1111/j.1365-2141.1986.tb02908.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Protective effect of a T-cell-dependent immunosuppressive, B-cell-mitogenic protein (F3'EP-Si, or P90) produced by Streptococcus intermedius.

Authors:  M Lima; A Bandeira; D Portnoi; A Ribeiro; M A Chaves
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

2.  Cellular changes during the infusion of high dose intravenous immunoglobulin.

Authors:  A C Newland; M G Macey; P A Veys
Journal:  Blut       Date:  1989-07

Review 3.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

Review 4.  Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.

Authors:  H I Atrah; R J Davidson
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

5.  Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.

Authors:  C Wadsworth; L A Hanson; H Kjellman; T Söderström; M Blombäck
Journal:  Blut       Date:  1989-03

6.  Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?

Authors:  L Padet; I St-Amour; É Aubin; R Bazin
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 7.  Harmful and beneficial antibodies in immune thrombocytopenic purpura.

Authors:  P A Imbach
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations.

Authors:  F Silvestris; P Cafforio; F Dammacco
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  In vitro synthesis of human IgE is suppressed by human IgG.

Authors:  H Haas; M Schlaak
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  Treatment of septic thrombocytopenia with immune globulin.

Authors:  E R Burns; V Lee; A Rubinstein
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.